These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19106386)

  • 1. Letter by Tarantini et al regarding article, "Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial nuclear substudy".
    Tarantini G; Razzolini R; Iliceto S
    Circulation; 2008 Dec; 118(25):e839; author reply e840-1. PubMed ID: 19106386
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter by Joshi regarding article, "Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial nuclear substudy".
    Joshi SB
    Circulation; 2008 Dec; 118(25):e838; author reply e840-1. PubMed ID: 19106385
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.
    Shaw LJ; Berman DS; Maron DJ; Mancini GB; Hayes SW; Hartigan PM; Weintraub WS; O'Rourke RA; Dada M; Spertus JA; Chaitman BR; Friedman J; Slomka P; Heller GV; Germano G; Gosselin G; Berger P; Kostuk WJ; Schwartz RG; Knudtson M; Veledar E; Bates ER; McCallister B; Teo KK; Boden WE;
    Circulation; 2008 Mar; 117(10):1283-91. PubMed ID: 18268144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.
    Teo KK; Sedlis SP; Boden WE; O'Rourke RA; Maron DJ; Hartigan PM; Dada M; Gupta V; Spertus JA; Kostuk WJ; Berman DS; Shaw LJ; Chaitman BR; Mancini GB; Weintraub WS;
    J Am Coll Cardiol; 2009 Sep; 54(14):1303-8. PubMed ID: 19778673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there an ischemic threshold beyond which percutaneous coronary intervention is beneficial in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial?
    Bangalore S; Messerli FH
    Am J Cardiol; 2007 Nov; 100(9):1495. PubMed ID: 17950818
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial.
    Maron DJ; Spertus JA; Mancini GB; Hartigan PM; Sedlis SP; Bates ER; Kostuk WJ; Dada M; Berman DS; Shaw LJ; Chaitman BR; Teo KK; O'Rourke RA; Weintraub WS; Boden WE;
    Am J Cardiol; 2009 Oct; 104(8):1055-62. PubMed ID: 19801024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial.
    Maron DJ; Boden WE; O'Rourke RA; Hartigan PM; Calfas KJ; Mancini GB; Spertus JA; Dada M; Kostuk WJ; Knudtson M; Harris CL; Sedlis SP; Zoble RG; Title LM; Gosselin G; Nawaz S; Gau GT; Blaustein AS; Bates ER; Shaw LJ; Berman DS; Chaitman BR; Weintraub WS; Teo KK;
    J Am Coll Cardiol; 2010 Mar; 55(13):1348-58. PubMed ID: 20338496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial: can we deliver on its promise?
    O'Gara PT
    J Am Coll Cardiol; 2010 Mar; 55(13):1359-61. PubMed ID: 20338497
    [No Abstract]   [Full Text] [Related]  

  • 9. Do major cardiovascular outcomes in patients with stable ischemic heart disease in the clinical outcomes utilizing revascularization and aggressive drug evaluation trial differ by healthcare system?
    Chaitman BR; Hartigan PM; Booth DC; Teo KK; Mancini GB; Kostuk WJ; Spertus JA; Maron DJ; Dada M; O'Rourke RA; Weintraub WS; Berman DS; Shaw LJ; Boden WE;
    Circ Cardiovasc Qual Outcomes; 2010 Sep; 3(5):476-83. PubMed ID: 20664026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Coronary revascularization: clinical features and indications].
    Alonso Martín JJ; Curcio Ruigómez A; Cristóbal Varela C; Tarín Vicente MN; Serrano Antolín JM; Talavera Calle P; Graupner Abad C
    Rev Esp Cardiol; 2005 Feb; 58(2):198-216. PubMed ID: 15743566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current analysis of the results of the COURAGE trial: has an optimal treatment been reached in clinical practice?
    Asín Cardiel E; Murga N
    Am J Cardiovasc Drugs; 2009; 9 Suppl 1():19-21. PubMed ID: 20000884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COURAGE under fire: on the management of stable coronary disease.
    Diamond GA; Kaul S
    J Am Coll Cardiol; 2007 Oct; 50(16):1604-9. PubMed ID: 17936162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial).
    Boden WE; O'Rourke RA; Teo KK; Maron DJ; Hartigan PM; Sedlis SP; Dada M; Labedi M; Spertus JA; Kostuk WJ; Berman DS; Shaw LJ; Chaitman BR; Mancini GB; Weintraub WS;
    Am J Cardiol; 2009 Jul; 104(1):1-4. PubMed ID: 19576311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The results of endovascular and surgical myocardial revascularization in patients with type II diabetes mellitus].
    Arablinskiĭ AV; Ovesian ZR; Kulikov AV; Shanoian AS
    Klin Med (Mosk); 2005; 83(5):14-8. PubMed ID: 15984575
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimal medical therapy is a proven option for chronic stable angina.
    O'Rourke RA
    J Am Coll Cardiol; 2008 Sep; 52(11):905-7. PubMed ID: 18772059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Coronary revascularization. State of the art].
    Alfonso F; Bermejo J; Segovia J
    Rev Esp Cardiol; 2005 Feb; 58(2):194-7. PubMed ID: 15743565
    [No Abstract]   [Full Text] [Related]  

  • 17. Changes in geographic variation in the use of percutaneous coronary intervention for stable ischemic heart disease after publication of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial.
    Mohan AV; Fazel R; Huang PH; Shen YC; Howard D
    Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):125-30. PubMed ID: 24347661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of chronic coronary disease: is the pendulum returning to equipoise?
    Boden WE
    Am J Cardiol; 2008 May; 101(10A):69D-74D. PubMed ID: 18474277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing scenario in chronic ischemic heart disease: therapeutic implications.
    Marzilli M; Affinito S; Focardi M
    Am J Cardiol; 2006 Sep; 98(5A):3J-7J. PubMed ID: 16931199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of regional ischemia after successful percutaneous intervention of bypassed native coronary chronic total occlusion: an application of the CART technique.
    Ho PC; Tsuchikane E
    J Invasive Cardiol; 2008 Jun; 20(6):305-8. PubMed ID: 18523326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.